US Stocks Move | Novo Nordisk continues to rise over 2% pre-market after five consecutive gains; CICC rates it "Outperform"

格隆汇2026/01/09 09:19

Show original

By:格隆汇

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Glonghui January 9th｜Novo Nordisk (NVO.US) continues to rise over 2% in pre-market trading, having previously recorded five consecutive days of gains. According to reports, CICC has given Novo Nordisk an “Outperform” rating with a target price of $73.50. The company is a global leader in metabolic diseases, with semaglutide driving growth in the GLP-1 market. The market size CAGR is expected to reach 23% from 2024 to 2030. The depth of the company’s pipeline supports future competition, with CagriSema and Amycretin expected to be launched in 2027/28, promoting an “alternating leadership” pattern. Strategic transformation into a comprehensive chronic disease platform is expected to enhance valuation premium potential.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Trump announced the formation of a federal "Artificial Intelligence Force" and the appointment of an AI affairs "chief," stating that AI could account for 25% of U.S. GDP. However, the responsibilities, funding, and leadership of the agency remain unclear, and its relationship with existing institutions is also uncertain. Internal White House advisors are divided on the extent of regulation, causing policy direction to be unstable.

华尔街见闻•2026/09/20 02:36

NEAR Protocol launches confidential perpetual futures, price breaks $2.827 resistance

Cointurk•2026/09/19 23:21